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Abstract
Background: In current practice, patients scheduled for radiotherapy are treated according to ‘rigid’ protocols with
predefined dose prescriptions that do not consider risk-taking preferences of individuals. The therapeutic operating
characteristic (TOC) graph is applied as a decision-aid to assess the trade-off between treatment benefit and
morbidity to facilitate dose prescription customisation.
Methods: Historical dose-response data from prostate cancer patient cohorts treated with 3D-conformal
radiotherapy is used to construct TOC graphs. Next, intensity-modulated (IMRT) plans are generated by optimisation
based on dosimetric criteria and dose-response relationships. TOC graphs are constructed for dose-scaling of the
optimised IMRT plan and individualised dose prescription. The area under the TOC curve (AUC) is estimated to
measure the therapeutic power of these plans.
Results: On a continuous scale, the TOC graph directly visualises treatment benefit and morbidity risk of physicians’
or patients’ choices for dose (de-)escalation. The trade-off between these probabilities facilitates the selection of an
individualised dose prescription. TOC graphs show broader therapeutic window and higher AUCs with increasing
target dose heterogeneity.
Conclusions: The TOC graph gives patients and physicians access to a decision-aid and read-out of the trade-off
between treatment benefit and morbidity risks for individualised dose prescription customisation over a continuous
range of dose levels.
Keywords: Radiotherapy, Treatment planning, Individualisation, Dose-response relations, Decision-making
Background
The main task in radiation dose prescription and treatment
planning is to maximise the tumour control probability
(TCP) while maintaining an acceptable normal tissue
complication probability (NTCP). Currently, this com-
promise is ‘frozen’ in treatment protocols, which are
based on consensus opinions about what is considered
to be the best trade-off for a specific patient population.
However, in an era where patient empowerment enters
into clinical practice, subjective criteria reflecting the
physician’s or individual patient’s risk-taking preferences
should inherently be taken into account to establish a
‘customised’ treatment. Therefore, individualised treatment
prescription and planning requires decision-making
based on TCP and NTCP scores rather than on dosimetric
criteria alone.
Amols et al. proposed an a posteriori decision-making
approach to rank existing treatment plans having different
combinations of TCP and NTCP based on a single figure
of merit quantifying the physician’s preferences [1]. An-
other approach is to extract patient preferences prior to
treatment. In a recent prospective trial involving patients
with localised prostate carcinoma scheduled for three-
dimensional conformal radiotherapy (3D-CRT), patients
were offered an a priori choice between treatments with
two alternative dose levels resulting in different probabilities
for tumour control and side-effects [2,3]. From this study, it
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became clear that the majority (79%) of patients opted to
be involved in the choice of their treatment once a
decision-aid was provided, and most patients attached a
higher weight to quality-of-life related aspects than to
tumour control [4].
The availability of modern treatment techniques pro-
vides the ability to design a variety of treatment plans
with divergent trade-offs between benefit and morbidity.
The ultimate way to take this variety into account is to
predict TCP and NTCP scores for the individual patient
based on the 3D dose distribution and fractionation scheme
applied. This is challenging, since the clinical outcome
measures for these treatments are not well known. Further-
more, specific tumour characteristics determining radiation
response (e.g., intrinsic radiosensitivity and hypoxia) are
often unknown for the individual patient. Nevertheless,
various models and parameter sets to estimate TCP and
NTCP from a 3D dose distribution have been developed
and applied (e.g., [5-8]). It is generally believed that these
models are adequate to rank rival treatment plans provided
they are used over the dose range from which they have
been derived. Some of these models have been incorporated
into modern treatment planning systems, enabling a
‘radiobiological’ evaluation of treatment plans. However,
the TCP/NTCP trade-off is difficult to assess in current
treatment planning systems, even for a simple ‘dose
scalarisation’ approach where only the prescription dose of
a given treatment plan is changed for either a fixed number
of fractions or for a fixed fraction dose. The concept of
maximizing the probability of uncomplicated tumour
control, P+, as a function of dose has been proposed to find
the single optimum dose level for this approach [9,10]. The
criticism against this measure is that an a priori ‘rigid’
trade-off between TCP and NTCP is assumed without
knowing their interrelationship over the range of potential
dose prescriptions. As such, it is not suitable as a single
measure for dose prescription customisation.
The aim of the present paper is to apply the concept of
the therapeutic operating characteristic (TOC) graph to
assess the trade-off in the TCP/NTCP domain over a con-
tinuous range of prescribed dose levels for given treatment
plans. The TOC graph is presented as an interactive tool for
dose prescription customisation of a treatment plan for an
individual patient. We compare the P+ and TOC graph and
discuss their value for individualised dose prescription opti-
misation. The concept is illustrated by a clinical example of
prostate cancer where the trade-off between 5-year bio-
chemical no evidence of disease (bNED5), late gastrointes-
tinal (GI) and genitourinary (GU) morbidity is studied.
Methods
Therapeutic operating characteristic (TOC) graph
The TOC is a parametric plot of TCP vs. NTCP with the
prescribed dose as a continuous independent parameter
[11-15]. As TCP and NTCP increase with total dose,
their interrelationship presents an ascending curve in
the benefit-injury decision space. The TOC graph can be
used to estimate the optimal level of therapeutic effect
and the associated dose level, based on individual risk-
taking preferences.
So far, few quantitative measures of therapeutic window
or therapeutic power have been published. Both refer to a
quality index for radiotherapy to achieve loco-regional
tumour control and to prevent severe late side effects. We
propose to use the area under the curve (AUC) of the
TOC graph as an index of the therapeutic power of a
treatment technique or plan, independent of consensus on
the prescribed dose level. This is by analogy with the AUC
of the ROC graph used in diagnostic radiology [16].
TOC graph for a patient population: modelling results
from clinical studies
The TOC graph was first applied to clinical outcome
data from a systematic literature review on the effects of
radiation dose on tumour control and morbidity in the
treatment of prostate cancer [3]. The trade-off between
TCP (i.e., bNED5), NTCPGI and NTCPGU (late GI and
GU morbidity Grade ≥2 RTOG) was assessed for
three-dimensional conformal radiotherapy (3D-CRT)
techniques of combined data from dose escalation
studies. The models and parameters used to describe
the dose-effect relationship for the patient population
studied are summarised in Additional file 1.
TOC graph for an individual patient: technique
assessment and dose prescription customisation
TCP and NTCP models derived from the literature were
applied to a 3D dose distribution of a given initial
treatment plan to construct TOC graphs by a posteriori
variation of the total prescription dose. This was either
accomplished by variation of the number of fractions
(at constant dose-per-fraction assuming no tumour cell
repopulation correction for overall treatment time) or
by variation of the fraction dose (while keeping the
number of fractions constant). TOC graphs were generated
after treatment planning to allow for TCP/NTCP balancing
and selection of the preferred prescription for therapy
delivery. Taking the individual’s risk-taking preferences
into account, a treatment plan with a customised dose
prescription can be selected as a point on the TOC
graph. We illustrate the concept of dose-level scaling
for a typical prostate cancer patient using different
treatment delivery and plan optimisation techniques in
a step-wise approach. Firstly, TCP/NTCP evaluation
was done for a forward planned 3D-CRT dose distribution
that had initially been designed for standard fractionation.
Secondly, a TOC graph was generated for an intensity-
modulated radiotherapy (IMRT) plan obtained by inverse
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planning using dose and dose-volume (i.e., physical) objec-
tives with equivalent initial prescribed dose (IMRTphys), as
it was expected that the NTCP of the IMRTphys plan was
lower under tumour iso-effective conditions than for the
3D-CRT plan. Then a third plan (IMRTbiol) was obtained
from the IMRTphys plan by physico-biological optimisation,
improving the TCP under isotoxic conditions. The hypo-
thetical benefit of scaling the IMRTbiol was also assessed.
TOC graphs and AUCs of the three plans were compared.
Organ segmentation and standard treatment plans
Both the 3D-CRT and IMRTphys plans had the same
dose prescription recipe: 78 Gy in 39 fractions satisfying
the 95% and 107% under- and overdosage criteria
according to ICRU 50 criteria. The planning target volume
(PTV) encompassed the prostate gland and base of the
seminal vesicles plus a 5 mm isotropic margin. The rectum
and bladder were delineated as organs at risk (OARs).
The 3D-CRT plan comprised a wedged 10 MV co-planar
4-beam arrangement. The IMRTphys plan encompassed a
10 MV co-planar 5-beam geometry and was generated for
a maximum of 60 step-and-shoot segments by inverse
treatment planning (Pinnacle3 version 7.6c; Philips
Radiation Oncology Systems, Fitchburg, USA) with direct
machine parameter optimisation (DMPO; RaySearch
Laboratories AB, Stockholm, Sweden).
Physico-biological treatment plan optimisation
For isotoxic optimisation, values for NTCPGI and
NTCPGU were calculated from the IMRTphys plan, and
constituted upper limits for the IMRTbiol plan at fixed
fraction number (N = 39). The physical objectives from
the IMRTphys plan were converted into constraints,
resulting in the following physico-biological optimisation
problem:
maximise TCP

D
 
subject to NTCPGI

D
 
≤ntcpGI
NTCPGU

D
 
≤ntcpGU
DVHi D;V j
 
≤dvhi;j
where D is the dose distribution to be optimised, and
ntcpGI, ntcpGU, dvhi,j are constraint values for organ i and
dose-volume constraint j as obtained from the IMRTphys
plan after it had been generated by inverse planning. Non-
clinical research software (ORBIT Workstation, version 1.5;
RaySearch Laboratories AB, Stockholm, Sweden) was used
to solve this problem with DMPO [17]. The dose-response
models used are summarised in Additional file 2.
For TOC analysis, treatment plans were retrieved from
Pinnacle3 and ORBIT Workstation into an in-house
developed software tool (MATLAB version 7.6.0;
The MathWorks Inc., Natick, USA). For the tumour a
conservative (α/β)T = 2 Gy adopted from [18] was
applied, while for both OAR endpoints generally
accepted values of (α/β)OAR = 3 Gy and 6 Gy were
adopted for Grade ≥2 late GI [19] and late GU toxicity
[20], respectively. These (α/β) ratios were used to account
for voxel-based fractionation correction prior to calculating
TCP and NTCP scores.
Results
TOC graph for patient population
Figure 1 illustrates the population-averaged dose-response
graphs for TCP and NTCP as a function of the prescribed
dose level in the 2 Gy equivalent dose (EQD2) range
of 60–80 Gy, obtained from a systematic literature
review [3].
In Figure 2A, two TOC graphs depict the trade-offs
between the TCP, NTCPGI, and NTCPGU of Figure 1
when plotted against each other. Figure 2B illustrates
the TOC graph zoomed in on the EQD2 range of 60–80
Gy for GI morbidity. In this graph, the dose level for
which the increase in TCP and NTCP with dose is equal,
and hence P+ = TCP – NTCP achieves its maximum
value, is 72 Gy with associated TCP = 75% and NTCP =
12%. Below this level, the gain in TCP per unit dose is
larger than the increase in NTCP, whereas the converse
is true beyond this level.
In Figure 3, the interdependence between TCP, NTCPGI
and NTCPGU as a function of the prescribed dose is shown
in a 3D TOC graph together with its 2D projections on the
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Figure 1 Dose response graphs obtained from systematic
literature review. TCP (green), NTCPGI (blue) and NTCPGU (red) as a
function of the prescribed total dose in 2 Gy fractions, obtained
from a systematic literature review over the dose range of 60–80 Gy
for 3D-CRT [3]. Dashed curves represent the relationship over
extrapolated dose ranges.
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TCP/NTCPGI and TCP/NTCPGU space that is shown in
Figure 2A.
TOC graphs for individual patient
In Figures 4A and 4B, TOC graphs are shown for the
initial (i.e., 39 × 2 Gy) 3D-CRT treatment plan (TCP = 83%,
NTCP = 25%) as a function of the scaled dose per fraction
and the number of fractions, respectively. Dose statistics
for renormalised plans are given in Table 1. It is evident
that both curves coincide at the nominal dose prescription
of 2 Gy per fraction or N = 39 fractions. Their relative pos-
ition in the TCP/NTCP space is insensitive to the model
parameters (TD50, γ37, m, a), and only depends on the ratio
of (α/β)T to (α/β)OAR. Since (α/β)T < (α/β)OAR, escalating
the total dose beyond the original 78 Gy level by adding
fractions will increase the TCP/NTCP ratio less than by
increasing the fraction dose. This becomes apparent from
Table 1 when comparing the TCP and NTCP scores for
the plans with a 5% nominally higher prescription dose of
82 Gy, obtained either from scaling the fraction size to 2.1
Figure 2 TOC graphs reconstructed from systematic literature review. TOC graphs showing (A) the trade-offs between TCP and either
NTCPGI (blue) or NTCPGU (red) over the dose range of 60–80 Gy in 2 Gy fractions (solid curve) and the extrapolated dose ranges (dashed curve).
In (B) the dashed line represents the tangent where TCP and NTCPGI equally increase with dose and defines the optimum of P+ = TCP - NTCP (○).
Dose levels in 2 Gy fractions are indicated (●) along the curve.
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Figure 3 3D TOC graph reconstructed from systematic literature review. Multidimensional TOC graph (black) for TCP, NTCPGI, and NTCPGU
as a function of the prescribed dose in 2 Gy fractions. Projection of TOC graphs for TCP vs. NTCPGU (red) and TCP vs. NTCPGI (blue) are shown.
Thin curves represent the relationship over extrapolated dose ranges; the 78 Gy plan is indicated (●).
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Gy (with 39 fractions) or from increasing the number of
fractions to 41 (with 2 Gy per fraction). The opposite
holds in case of dose de-escalation below 78 Gy and for
(α/β)T > (α/β)OAR. When plotted in the same graph, both
TOC curves would coincide only if (α/β)T = (α/β)OAR.
In Figure 5, TOC graphs for the 3D-CRT, IMRTphys, and
IMRTbiol plans for the same patient anatomy are shown.
Dose statistics for the initial plans are given in Table 2. By
comparing the TOC graphs for the 3D-CRT and the
IMRT plans, it is obvious that the IMRTphys plan has a
more conformal dose distribution than the 3D-CRT plan,
reducing NTCP (from 25% to 13%) at constant TCP = 83%.
Comparison of the TOC graphs for the IMRTphys
and the IMRTbiol plan suggests that an increase in
TCP (from 83% to 87%) can be obtained at constant
NTCP =13%. It can be seen that the three TOC graphs
do not cross and have different AUCs (3D-CRT: 0.87,
IMRTphys: 0.91, IMRTbiol: 0.93). The IMRTbiol plan
outperforms the IMRTphys plan over the whole range of
prescribed dose levels and fractionation schemes, whereas
the latter outperforms the 3D-CRT plan. By comparing the
TOC graphs, its use for prescription dose customisation
becomes apparent; when rescaling a given treatment plan
does not fulfill the TCP/NTCP trade-off requirements, only
re-optimization (with more direct steering of the TCP/
NTCP criteria) will improve the quality of the plan.
Figure 4 TOC graphs for fraction size and fraction number variation. TOC graphs for prostate 3D-CRT plan showing trade-off between TCP
and NTCPGI as a function of (A) the dose-per-fraction scale factor (at constant fraction number) and (B) the number of fractions N (at constant
fraction dose). The initial plan (39 × 2 Gy) is marked (○) at the 100% dose level and at N = 39, respectively.
Table 1 Dose and response statistics for renormalised 3D-CRT plans
Dose-per-fraction (N = 39) Number of fractions (2 Gy/fraction)
95% 100% 105% N = 37 N = 39 N = 41
prostate
Dmin 73.2 77.1 80.9 73.1 77.1 81.1
Dmean 74.3 78.2 82.1 74.2 78.2 82.2
Dmax 75.1 79.1 83.1 75.0 79.1 83.2
TCP 76% 83% 89% 78% 83% 87%
rectum
Dmean 45.3 47.7 50.1 45.3 47.7 50.1
Dmax 74.9 78.9 82.8 74.9 78.9 82.9
NTCPGI 13% 25% 44% 16% 25% 38%
bladder
Dmean 31.6 33.3 34.9 31.6 33.3 35.0
Dmax 74.0 77.9 81.8 73.9 77.9 81.9
NTCPGU 13% 15% 16% 13% 15% 19%
Abbreviations: N, number of fractions; Dmin, minimum dose; Dmean, mean dose; Dmax, maximum dose, TCP, tumour control probability, NTCPGI, probability of late
gastrointestinal morbidity; NTCPGU, probability of late genitourinary morbidity.
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Figure 5 clearly shows that both the TOC’s shape and
its AUC help to estimate the therapeutic power of a
treatment plan over a continuous range of TCP and
NTCP scores. Finally, the TOC graph of the best
performing (IMRTbiol) plan can be presented to the
physician and/or patient to assess the trade-off between
treatment benefit and morbidity and to choose from the
TOC graph the dose-level that best fits their preferences.
Discussion
In an era of individualised cancer therapy, radiotherapy
should move towards customised dose prescription in
order to maximise individual patient’s outcome and
quality of life. The currently applied ‘rigid’ treatment
protocols neither take into account the anatomical diver-
sity of patients within the risk group nor their individual
risk-taking preferences. The standard strategy will lead
to relative underdosage in individuals who are willing to
tolerate a higher radiation dose aiming for tumour
control, whilst relatively overdosing those not willing to
accept the possible adverse effects resulting from the
predefined radiation dose. Hence, there is a need to
move toward customised treatment planning where
individualisation is not restricted to adapting the spatial
dose distribution to the patient’s anatomy, but also
involves balancing of treatment benefit and morbidity in
terms of TCP and NTCP.
As an overture towards individualised TCP and NTCP
risk balancing, we conducted a prospective decision-
making trial in patients with localised prostate carcinoma
scheduled for 3D-CRT, who were offered an a priori
restricted choice between treatments with two alternative
pre-selected dose levels [2]. To take this one step further,
a tool to depict a continuum of clinically relevant dose
levels and their corresponding TCP and NTCP indices
would be helpful to assist selecting an optimum dose level
after an initial treatment plan has been generated for the
individual patient.
In previous work by Lind et al., the concept of maximiz-
ing the probability of uncomplicated tumour control, P+, as
a function of dose has been proposed to find the optimum
dose level [10]. It should be noted that the TOC graph pro-
vides unbiased information in comparison to the P+ graph
when plotted as a function of dose. This becomes clear
when the general expression for P+ is considered:
Pþ ¼ TCP  NTCP þ δ NTCP 1 TCPð Þf gð Þ; ð1Þ
where δ is the estimated fraction of patients for which
tumour and normal tissue response are statistically
independent (0 ≤ δ ≤ 1) [9]. Expression (1) assumes that
an implicit a priori trade-off between TCP and NTCP is
made. For example, with δ = 0 equation (1) reduces to
P+ = TCP – NTCP, assuming that the risk of recurrence is
equally important as the risk of suffering from (severe)
side effects. Therefore, P+ has often been criticised as a
measure that does not reflect the clinical reality that
reductions in TCP are rated differently from the risk of
complications by clinicians and patients. By plotting TCP
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Figure 5 TOC graphs for 3D-CRT, IMRTphys and IMRTbiol plans.
TOC graphs for TCP vs. NTCPGI obtained by dose level scaling of a
prostate 3D-CRT plan (solid curve), the IMRTphys plan (dashed curve),
and the IMRTbiol plan (dotted curve) at constant fraction number,
N = 39. Symbols (● , ○, □) represent the TCP and NTCP scores of
the initial plans.
Table 2 Dose and response statistics for initial treatment
plans (39 fractions)
3D-CRT IMRTphys IMRTbiol
prostate
Dmin 77.1 75.4 74.1
Dmean 78.2 78.8 81.8
Dmax 79.1 81.8 97.0
TCP 83% 83% 87%
rectum
Dmean 47.7 36.8 36.3
Dmax 78.9 80.1 84.7
NTCPGI 25% 13% 13%
bladder
Dmean 33.3 25.1 17.7
Dmax 77.9 82.4 93.8
NTCPGU 15% 14% 14%
Abbreviations: 3D-CRT, three-dimensional conformal radiation therapy; IMRTphys,
physically optimised IMRT plan; IMRTbiol, physico-biologically optimised IMRT
plan; Dmin, minimum dose; Dmean, mean dose; Dmax, maximum dose, TCP,
tumour control probability, NTCPGI, probability of late gastrointestinal
morbidity; NTCPGU, probability of late genitourinary morbidity.
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vs. NTCP with the prescribed dose as an independent
parameter, no assumption with regard to a priori risk-
taking preferences between TCP and NTCP is made.
Instead, their interrelationship is assessed over the whole
range of potential dose levels to facilitate the selection of
an optimum that satisfies the risk-taking preferences of
the individual clinician or patient. Using the full TOC
graph instead of selecting the single dose level where P+ is
maximal pre-empts the criticism against a priori balancing
the TCP/NTCP trade-off.
In the 1970’s Moore and Mendelsohn proposed the
TOC curve as a method to optimise treatment levels in
cancer therapy [11] and later on, it was used in studies
on radiation therapy for head and neck tumours [12-14].
However, this concept has only been employed to deter-
mine an optimum dose level for a patient population in
a ‘one size fits all’ approach. We emphasize that with the
current possibilities and knowledge of inverse treatment
planning techniques (e.g., by explicitly incorporating
dose-response relationships into the optimization as
objective and/or constraint functions) the application
options for individualized dose prescription strategies may
be more important and clinically relevant than before.
The TOC graph used in the current work provides a
means to visualise and explore the trade-off between
TCP and NTCP in an intuitive manner to be used as a
tool for a posteriori dose prescription customisation of
an initial treatment plan for an individual patient. Plans
with different TCP/NTCP trade-offs can be generated
from the same underlying relative dose distribution by
scaling of the prescribed dose or fractionation scheme.
Since no re-planning is required, the TOC graph can be
generated off-line. Furthermore, this approach facilitates
the interactive balance between TCP and NTCP of a
given plan after treatment planning and plan optimisation
and does not require risk-taking predilections to be articu-
lated a priori, as is the case in today’s inverse treatment
planning approaches. Additionally, by exploiting the AUC,
a quantitative definition of the therapeutic power is
provided independent of consensus on the dose level.
The clinical application of changing the prescribed
dose and fractionation after an initial treatment plan has
been generated has recently gained renewed interest as
part of individualised dose prescription strategies that
escalate the tumour dose until maximally tolerable
NTCP limits are reached in, for example, non-small cell
lung cancer radiotherapy [6,7,21,22]. Current treatment
planning systems lack the means to assess the effects of
dose or fractionation variation of a given treatment plan
in terms of TCP and NTCP indices and do not provide
insight in their interrelationship. Consequently, it is
common practice to completely re-design and re-
calculate a treatment plan once the dose description or
fractionation schedule has changed. Our re-scaling
approach together with the TOC concept brings
individualised dose prescription into clinical practice by
providing an intuitive and easy-to-apply tool to find the
preferred prescription dose for either a fixed number of
fractions (by changing the dose per fraction) of for fixed
fraction dose (by changing the number of fractions)
which yields pre-selected NTCP limit(s) for the OAR(s).
Practical use of TOC graph
To exploit our concept in the clinical workflow, first, a
TOC graph is generated from historical dose-response
data that were derived for a group of patients treated
with the same irradiation technique but with different
dose prescriptions. The individual patient and the radiation
oncologist interactively choose TCP/NTCP coordinates
from the TOC graph in a first decision-making step, which
results in an intended dose prescription. Subsequently, an
initial treatment plan is designed for the intended dose
prescription based on the individual patient’s anatomy.
Hence, the population-based TOC can be used to establish
an evidence-based ‘customised’ dose prescription for a
given treatment technique prior to designing a treatment
plan for the intended dose prescription level. Finally, a sec-
ond decision-making step is required to further customise
the dose prescription by re-normalisation and to achieve at
least the desired, but likely superior, TCP/NTCP scores.
Physico-biological treatment plan optimisation
We showed that constrained optimisation in inverse
planning based on TCP and NTCP models resulted in
an iso-toxic treatment plan with improved TCP. As the
TCP model allows for some degree of dose heterogeneity
in the PTV, a dose reduction in parts of the PTV is
exploited to reduce the NTCP, whereas in other parts
the dose is escalated. A steep dose fall-off at the border
of the PTV keeps the TCP constant, and allows for better
sparing of the OAR, which facilitates dose escalation
resulting in the same NTCP with higher TCP.
Relation of TOC graph to Pareto efficient frontier
The TOC graph should not be confused with the Pareto
efficient frontier (PEF) that has been discussed in radio-
therapy lately (e.g., [23]). The principles of TOC and PEF
are fundamentally different. Whereas the TOC graph has
been obtained from scaling a single treatment plan, a PEF
would have required the physico-biological optimisation
problem to be repeatedly solved to optimality for different
a priori set NTCP constraint values. A comparison
between the TOC and PEF is however beyond the scope
of this paper and will be addressed in another paper by
the authors.
Due to uncertainties in the radiobiological models, the
choice for a final dose level should not solely be based on
the TOC graph, but should always include the underlying
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3D dose distribution. Preferably, the TOC graph should be
presented together with the model parameters, TCP/
NTCP values, and confidence levels [13].
However, confidence intervals for all model parameters
are not available or may be unreliable for IMRT dose
distributions, as they have mainly been derived from 3D
conformal radiotherapy dose distributions. As more
clinical data comes available the TOC-based estimate of
the optimal dose level will get more trustworthy. We
therefore recommend to carefully introduce the TOC
into clinical practice, by gradually releasing the interval
of dose-level re-scaling towards values where the uncer-
tainties are largest. The true value of the TOC graph
and underlying TCP/NTCP models should be assessed
in clinical trials comparing the predicted and actual
TCP and NTCP values.
Conclusions
For an individual patient, the TOC graph can be
exploited as an a posteriori decision aid in risk-adapted
dose prescription customisation of a given treatment
plan as a function of the prescribed dose level or the
number of fractions. It provides physicians and patients
with a decision aid for individual risk-taking preferences
in terms of TCP/NTCP trade-off. The AUC is a dose
level independent measure of the therapeutic power of a
treatment plan.
Additional files
Additional file 1: TCP and NTCP models used in systematic
literature review.
Additional file 2: TCP and NTCP models used by ORBIT
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